Bendamustine for refractory Hodgkin’s lymphoma, is it good enough?

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Bendamustine for refractory Hodgkin’s lymphoma, is it good enough?

4th World Congress on Cancer Science & Therapy

October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Hesham Mourad

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

This lecture will review the current role for bendamustine in refractory Hodgkin?s Lymphoma. Several articles and case reports will be reviewed and evaluated to define the current role of bendamustine in those patients. Also recommendations from the current guidelines will be evaluated based on those articles. In addition to these subjects, attendees of this lecture will able to decide when to use bendamustine in those selected patient.

Biography :

Hesham Mourad is a Doctor of Pharmacy graduated in 2011. He completed a general pharmacy residency in 2012. After that he worked as clinical pharmacist in a community teaching hospital primarily in critical care and outpatient oncology practice. He co-authored two oncology related case reports which he participated in the treatment decision making process. one case was published in the Journal of the National Comprehensive Cancer Network and the other case was published in Journal of Oncology Pharmacy Practice. He is also board certified pharmacotherapy specialist.

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

arrow_upward arrow_upward